Recent breakthroughs in the field of regenerative medicine continue to support the tremendous healing potential of stem cell therapy. Until a few years ago, stem cell research was limited to only what could be gathered from the research gathered from embryonic stem cells; this research was limited by the well-documented ethical concerns surrounding the practice…
Multiple sclerosis (MS) is a progressive and disabling autoimmune disease that affects the brain and central nervous system. As MS progresses, the body’s immune system attacks the protective sheath (myelin) that covers nerve fibers resulting in axonal damage and loss that eventually results in paralysis of the limbs; the condition also contributes to a number…
Progressive multiple sclerosis is a significant disruptive neurodegenerative disease that interferes with the brain’s ability to control the body; the condition continues to get worse over time and, to date, has no known therapeutic treatment or cure. Petrou Et. Al’s double-blind clinical trial examined the therapeutic efficacy of mesenchymal stem cell (MSC) transplantation in active…
Glaucoma is a complex group of interrelated eye conditions that affects over 70 million people worldwide. A leading cause of irreversible blindness in people over 60, glaucoma is a progressive condition that affects the optic nerve and leads to gradual loss of specific neurons that relay visual information from the retina to the brain; the…
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease or Lou Gehrig’s disease, is a disease that gradually paralyzes people because the brain is no longer able to communicate with the muscles of the body that we are typically able to move at will[1]; as ALS progresses, people will lose the ability to walk,…
After a decade of research, the safety and efficacy of intravenous infusion of bone-marrow-derived stem cells for therapeutic treatment in individuals with heart failure have been well established; however, until Bartolucci et al’s phase 1 / 2 randomized controlled trial of intravenous infusion umbilical cord mesenchymal stem cells (UC-MSCs) on heart disease, no clinical studies…
Multiple system atrophy (MSA) is a rare, progressively degenerative neurological disorder that affects several of the central nervous system’s involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. Similar to Parkinson’s disease in both symptoms and progression, MSA has an average survival time of 7-9 years with no known treatment; the condition…
We have answers. Speak with a Stemedix Care Coordinator today with no obligation. Give us a call!